NEWS AND VIEWS FROM THE PHARMACEUTICAL FINE CHEMICAL AND CUSTOM MANUFACTURING SECTOR

Wednesday 3 November 2010

GAO unhappy with FDA inspections

The US General Accountability Office has reported that the FDA failed to implement earlier recommendations that would close the gap between the agency’s approach to inspecting domestic and foreign drug manufacturing facilities. Despite a budget increase from $12m in 2008 to $41m in 2009, the agency only inspected 11% of foreign facilities and 42% of US facilities.
Pharmalot

No comments: